UK govt delays new PPRS cuts to February 2009; OFT "value-pricing" included in deal

24 November 2008

A compromise arrangement has been reached between the UK government and the Association of the British Pharmaceutical Industry to delay price cuts from the newly-negotiated Pharmaceutical Price Regulation Scheme by one month. The Department of Health, in a statement, said the deal "means that more patients will benefit from a wider range of innovative drug treatments at a fair price to the National Health Service." Its objective is to cut the NHS' annual drug bill of about L11.0 billion ($16.50 billion).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight